Melanóma: nyitott vizsgálatok itt: Brazília
9 trials · From ClinicalTrials.gov, checked 2026. nov. 10.. Ask the study team whether a trial fits you.
1. fázisToborozTrial-stage medicine
Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma
- Where
- Bento Gonçalves, Ijuí, Pará, Porto Alegre, Rio de Janeiro, Santa Catarina, São Paulo
- Age
- 18 év and over
- People
- 120 worldwide
- Run by
- Biocon Biologics UK PLC
See details and how to joinNCT07476326EU 2025-525158-20-00Regiszter frissítve: 2026-11-06
3. fázisToborozTrial-stage medicine
Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma
- Where
- Barretos, Belo Horizonte, Bento Gonçalves, Blumenau, Caxias do Sul, Ijuí, Jaú, Lajeado, Natal, Porto Alegre, Ribeirão Preto, Rio de Janeiro, Santa Cruz do Sul, São Caetano do Sul, São Paulo, Sorocaba
- Age
- 18 év and over
- People
- 632 worldwide
- Run by
- mAbxience Research S.L.
See details and how to joinNCT07221734Regiszter frissítve: 2026-10-29
1/2. fázisToborozTrial-stage medicine
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Where
- Barretos, Florianópolis, Jaú, Porto Alegre
- Age
- 18 év and over
- People
- 680 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06330064EU 2023-509632-26-00Regiszter frissítve: 2026-10-26
1. fázisToborozTrial-stage medicine
Pharmacokinetics, Safety, and Immunogenicity of Bmab1800 and Keytruda® as Adjuvant Monotherapy in Patients With Melanoma
- Where
- Barretos
- Age
- 18 év to 99 év
- People
- 138
- Run by
- Biocon Biologics UK PLC
See details and how to joinNCT07581509Regiszter frissítve: 2026-10-02
1/2. fázisToborozTrial-stage medicine
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
- Where
- São Paulo
- Age
- 6 hónap to 17 év
- People
- 370 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT02332668EU 2022-501257-36-00Regiszter frissítve: 2026-07-06
No phaseToborozResearch participation
NEOSENT: Early Anti-PD-1 Therapy In High-Risk Stage II Melanoma
- Where
- São Paulo
- Age
- 18 év and over
- People
- 250
- Run by
- AC Camargo Cancer Center
See details and how to joinNCT07680699Regiszter frissítve: 2026-07-02
3. fázisToborozTrial-stage medicine
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
- Where
- Barretos, Brasília, Florianópolis, Fortaleza, Ijuí, Liberdade, Porto Alegre, Rio de Janeiro, São Paulo
- Age
- 18 év and over
- People
- 680 worldwide
- Run by
- Immunocore Ltd
See details and how to joinNCT06112314Regiszter frissítve: 2026-02-25
3. fázisToborozTrial-stage medicine
Photodynamic Therapy Associated With Sonodynamic Therapy for the Treatment of Nodular Basal Cell Carcinoma
- Where
- Jaú
- Age
- 18 év and over
- People
- 142
- Run by
- University of Sao Paulo
See details and how to joinNCT07381972Regiszter frissítve: 2026-02-02
1/2. fázisCsak meghívásosTrial-stage medicine
Melphalan Chemoreduction for Ocular Melanoma
- Where
- Ribeirão Preto
- Age
- 18 év and over
- People
- 10
- Run by
- Hospital das Clínicas de Ribeirão Preto
See details and how to joinNCT05893654Regiszter frissítve: 2025-09-15
Minden vizsgálat (Melanóma) és a térkép
Ez az oldal nem orvosi tanács. Mielőtt egy vizsgálatot megkeresel, beszélj az orvosoddal.